ABILIFY MAINTENA KIT
Clinical safety rating: caution
Abilify Maintena Kit contains aripiprazole extended-release injectable suspension, an atypical antipsychotic used for the maintenance treatment of schizophrenia in adults. It is administered once monthly via intramuscular injection.
Aripiprazole is a partial agonist at D2 and 5-HT1A receptors and an antagonist at 5-HT2A receptors, stabilizing dopamine and serotonin activity.
| Metabolism | Primarily hepatic via CYP2D6 and CYP3A4; active metabolite dehydro-aripiprazole. |
| Excretion | Renal (approximately 25% unchanged and 55% as metabolites); fecal (approximately 20% as metabolites). |
| Half-life | Aripiprazole: 75-146 hours; dehydro-aripiprazole: 94-146 hours. Long half-life allows monthly intramuscular dosing. |
| Protein binding | Aripiprazole is >99% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Aripiprazole: 4.9 L/kg (range 3.7-7.2 L/kg), indicating extensive tissue distribution. |
| Bioavailability | IM (Abilify Maintena): 100% relative to oral aripiprazole after 5 monthly doses; oral: 87%. |
| Onset of Action | IM: Therapeutic effects typically observed within 1-2 weeks, though full response may take up to 4-6 weeks. |
| Duration of Action | IM: Duration of action is approximately 30 days due to extended-release formulation; steady-state achieved after 4 months of monthly dosing. |
| Molecular Weight | 448.39 |
| Action Class | Atypical antipsychotic |
400 mg IM once monthly after establishing tolerability with oral aripiprazole.
| Dosage form | FOR SUSPENSION, EXTENDED RELEASE |
| Renal impairment | No adjustment for mild/moderate impairment; caution in severe impairment (CrCl <30 mL/min). |
| Liver impairment | No adjustment for mild impairment; moderate to severe (Child-Pugh class B or C): reduce dose to 300 mg/month. |
| Pediatric use | Not approved for pediatric use. |
| Geriatric use | Use cautiously due to increased sensitivity; consider lower doses and monitor for adverse effects. |
| 1st trimester | Aripiprazole crosses the placenta. Studies suggest a potential risk of congenital malformations, particularly neural tube defects, but data are limited. Use only if benefit outweighs risk. |
| 2nd trimester | Risk of fetal growth restriction and preterm birth. Monitor fetal growth. Use only if clearly needed. |
| 3rd trimester | Risk of neonatal withdrawal (e.g., agitation, hypotonia) and extrapyramidal symptoms after delivery. Consider tapering before delivery if possible. |
Clinical note
Use during pregnancy only if potential benefit justifies potential risk to fetus; may cause extrapyramidal and/or withdrawal symptoms in neonates.
| Placental transfer | Aripiprazole crosses the placenta; cord blood concentrations are approximately 20-50% of maternal plasma levels. Evidence indicates significant transfer. |
| Breastfeeding | Aripiprazole is excreted into human breast milk in low levels. The relative infant dose is estimated at 2-4% of maternal weight-adjusted dose. Monitor infant for drowsiness, poor feeding, and developmental milestones. Consider benefits of breastfeeding against potential risks. |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
| Common Effects | Nausea, vomiting, constipation, headache, dizziness, akathisia, insomnia, weight gain |
| Serious Effects | Neuroleptic malignant syndrome (NMS), tardive dyskinesia, stroke in elderly with dementia, suicidal thoughts/behaviors. |
Hypersensitivity to aripiprazole or any excipientsConcurrent use with other medications that prolong the QT interval in patients with known QTc prolongation
| Precautions | Increased mortality in elderly dementia patients; suicidal thoughts and behaviors; neuroleptic malignant syndrome; tardive dyskinesia; metabolic changes (hyperglycemia, dyslipidemia, weight gain); orthostatic hypotension; leukopenia/neutropenia; seizure risk; dysphagia; body temperature dysregulation; pathological gambling and other impulse control disorders. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Limited data, but aripiprazole is not a major human teratogen based on available studies. Second and third trimesters: Neonates exposed to antipsychotics, including aripiprazole, during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms post-delivery. |
| Fetal Monitoring | Monitor maternal weight, blood pressure, glucose levels, and psychiatric status. For neonates, monitor for extrapyramidal symptoms, sedation, and feeding difficulties. |
| Fertility Effects | Hyperprolactinemia, potential due to dopamine D2 receptor antagonism, may cause menstrual irregularities, galactorrhea, and reduced fertility. Aripiprazole has lower prolactin elevation risk compared to other antipsychotics. |
| No specific food interactions. Grapefruit/grapefruit juice may increase aripiprazole levels (CYP3A4 inhibition). Avoid excessive alcohol consumption. |
| Clinical Pearls | Administer every 4 weeks by intramuscular injection only. Do not substitute for oral aripiprazole on a mg-per-mg basis due to different pharmacokinetics. Requires initiation and continuation with oral aripiprazole for 14 days to establish tolerability. Monitor for neuroleptic malignant syndrome, tardive dyskinesia, and metabolic changes. Dose adjustments needed in patients with known CYP2D6 poor metabolizer status or concurrent use of strong CYP2D6 or CYP3A4 inhibitors. |
| Patient Advice | This medication is given as an injection every 4 weeks by a healthcare professional. · Do not stop taking your oral aripiprazole until your doctor tells you to. · Seek emergency care if you experience fever, muscle stiffness, confusion, or irregular heartbeat. · Avoid alcohol and driving until you know how this medicine affects you. · Report any uncontrolled movements of the face, tongue, or other body parts to your doctor. · Tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. |